Seattle Genetics and Genmab A/S announced the positive results from the innovaTV 204 Key Phase II study, which involves the use of antibody-drug conjugate (ADC) tisotumab vedotin for the treatment of cervical cancer. The results show that Tesotoma alone has significant efficacy as a monotherapy and can provide clinically meaningful and long-lasting objective effects.
Tissue factor (TF) is a transmembrane protein involved in tumor signal transduction and angiogenesis. TF is highly expressed in many solid tumors, including cervical cancer, ovarian cancer, prostate cancer, bladder cancer, esophageal cancer, endometrial cancer and lung cancer lung, pancreas, colorectal, and head and neck cancers. Due to the high expression and rapid internalization of TF factor in many solid tumors, TF has become an ideal target for the development of ADC drugs.
Figure 1: Mechanism of action of tisotumab vedotin (Image from immunopaedia.org.za)
Tisotumab vedotin, also known as HuMax-TF, is an antibody-drug conjugate or ADC targeting tissue factor (TF). An antibody targeting tissue factor (TF) is conjugated with effective microtubule disrupting agent monomethyl auristatin E (MMAE) through a cleavable linker, maleimidohexanoyl-pentyl-citrulline-p-amino benzyloxy carbonyl (mc-Val -cit-PABC).
Currently, tisotumab vedotin is being jointly developed by Seattle Genetics and Genmab as a monotherapy or in combination with other therapies to treat recurrent and/or metastatic cervical cancer, ovarian cancer, and other solid tumors.
See more articles：